says the December quarter (Q3 FY26) is expected to be its best-ever, backed by record order-book visibility and steady execution. Management is guiding for FY26 revenue to exceed ₹335 crore (and has also reiterated confidence on FY26 PAT guidance in its business update coverage), keeping expectations elevated into H2. Regulatory message There’s no regulatory trigger here—the market impact is disclosure-led: when companies pre-guide “best-ever” quarters, the bar shifts from growth to the quality of growth (repeatability, margins, working capital discipline). Any slippage in dispatches, tender timing, or receivables can quickly turn a narrative upgrade into a credibility test. Industry-wide implications This kind of forward guidance is becoming the playbook for small/midcap consumer-health exporters: lock in visibility, talk up execution, and let re-rating follow. But it also tightens peer pressure—investors will benchmark order-book conversion and cash flows, not just topline targets. What must change now Cupid needs to show three proofs: order-book conversion without margin dilution, controlled receivables as volumes scale, and clarity on what drives the “best-ever” quarter (exports vs India FMCG mix). Investors should watch for consistency across Q4 commentary—because one record quarter is a spike; two is a pattern. Source: Economic Times No Recommendation

#FundamentalViews#EquityResearch